Table 2.

Multivariate analysis of progression-free survival in the BRAF-mutant PTC cohort.

Variable	HR	95% CI	P value
Risk score	1.614	1.199-2.173	0.002
Age at diagnosis	0.977	0.940-1.017	0.257
Sex	0.995	0.437-2.262	0.990
Neoplasm disease stage	1.509	0.905-2.515	0.115
Metastasis stage	1.835	0.884-3.812	0.103
Lymph node stage	1.139	0.598-2.168	0.692
Tumor stage	1.838	1.228-2.750	0.003
Radiotherapy	1.241	0.522-2.952	0.624

Bold values indicate statistically significant (P<0.05).